Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ResToP: Reinduction and Second Stop of TKI With Ponatinib in CML
NCT04160546Phase 2Completed
- Sponsor
- Fundación CRIS contra el Cáncer
- Start
- Jan 2020
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in chronic myeloid leukemia (CML), sponsored by Fundación CRIS contra el Cáncer. Primary endpoint: Major Molecular Response at 52 weeks. Started Jan 2020; status: completed.
02
Drugs
ponatinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04160546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04160546.